Mayo specialist for Cytopia

By Dylan Bushell-Embling
Wednesday, 30 July, 2008

Cytopia [ASX: CYT] has appointed a study chair for Phase I clinical trials of its new JAK2 enzyme inhibitor.

Dr Ayalew Tefferi is professor of medicine in haematology at the Mayo Clinic College of Medicine in the US.

JAK2 is a mutant enzyme which occurs in myelofibrosis patients, a disorder which causes bone marrow to be replaced by fibrous scar tissue. JAK2 can also cause other blood disorders, many of which can lead to conditions such as leukemia.

Cytopia expects to be ready to file an Investigational New Drug application for the treatment with the US FDA by the end of the year.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd